A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2009

At a glance

  • Drugs Sotatercept (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 11 Sep 2009 Pharmacodynamic outcomes have been presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research.
    • 08 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top